Jpmorgan Chase & CO Nautilus Biotechnology, Inc. Transaction History
Jpmorgan Chase & CO
- $1.14 Trillion
- Q2 2024
A detailed history of Jpmorgan Chase & CO transactions in Nautilus Biotechnology, Inc. stock. As of the latest transaction made, Jpmorgan Chase & CO holds 37,617 shares of NAUT stock, worth $97,804. This represents 0.0% of its overall portfolio holdings.
Number of Shares
37,617
Previous 64,001
41.22%
Holding current value
$97,804
Previous $188,000
53.19%
% of portfolio
0.0%
Previous 0.0%
Shares
12 transactions
Others Institutions Holding NAUT
# of Institutions
82Shares Held
63.9MCall Options Held
2.9KPut Options Held
500-
Ah Equity Partners Bio Ii, L.L.C. Menlo Park, CA16.3MShares$42.4 Million24.08% of portfolio
-
Perceptive Advisors LLC New York, NY12.6MShares$32.7 Million0.85% of portfolio
-
Cercano Management LLC Bellevue, WA7.17MShares$18.6 Million0.45% of portfolio
-
Madrona Venture Group, LLC6.02MShares$15.7 Million15.03% of portfolio
-
Black Rock Inc. New York, NY3.83MShares$9.95 Million0.0% of portfolio
About Nautilus Biotechnology, Inc.
- Ticker NAUT
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 124,663,000
- Market Cap $324M
- Description
- Nautilus Biotechnology, Inc., a development stage life sciences company, engages in creating a platform technology for quantifying and unlocking the complexity of the proteome. It develops Nautilus Platform, a proteomics platform that includes end-to-end solution comprised of instruments, consumables, and software analysis. The company was found...